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Abstract
Background: Cytokine flow cytometry (CFC) or intracellular cytokine staining (ICS) can
quantitate antigen-specific T cell responses in settings such as experimental vaccination.
Standardization of ICS among laboratories performing vaccine studies would provide a common
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BMC Immunology 2005, 6:13 http://www.biomedcentral.com/1471-2172/6/13platform by which to compare the immunogenicity of different vaccine candidates across multiple
international organizations conducting clinical trials. As such, a study was carried out among several
laboratories involved in HIV clinical trials, to define the inter-lab precision of ICS using various
sample types, and using a common protocol for each experiment (see additional files online).
Results: Three sample types (activated, fixed, and frozen whole blood; fresh whole blood; and
cryopreserved PBMC) were shipped to various sites, where ICS assays using cytomegalovirus
(CMV) pp65 peptide mix or control antigens were performed in parallel in 96-well plates. For one
experiment, antigens and antibody cocktails were lyophilised into 96-well plates to simplify and
standardize the assay setup. Results (CD4+cytokine+ cells and CD8+cytokine+ cells) were
determined by each site. Raw data were also sent to a central site for batch analysis with a dynamic
gating template.
Mean inter-laboratory coefficient of variation (C.V.) ranged from 17–44% depending upon the
sample type and analysis method. Cryopreserved peripheral blood mononuclear cells (PBMC)
yielded lower inter-lab C.V.'s than whole blood. Centralized analysis (using a dynamic gating
template) reduced the inter-lab C.V. by 5–20%, depending upon the experiment. The inter-lab C.V.
was lowest (18–24%) for samples with a mean of >0.5% IFNγ + T cells, and highest (57–82%) for
samples with a mean of <0.1% IFNγ + cells.
Conclusion: ICS assays can be performed by multiple laboratories using a common protocol with
good inter-laboratory precision, which improves as the frequency of responding cells increases.
Cryopreserved PBMC may yield slightly more consistent results than shipped whole blood.
Analysis, particularly gating, is a significant source of variability, and can be reduced by centralized
analysis and/or use of a standardized dynamic gating template. Use of pre-aliquoted lyophilized
reagents for stimulation and staining can provide further standardization to these assays.
Background
Enzyme-linked immunospot (ELISPOT) and cytokine
flow cytometry (CFC) (or more specifically, intracellular
cytokine staining (ICS)) are popular methods for single-
cell analysis of antigen-specific T cell cytokine production.
T cell production of IFNγ, and increasingly also IL-2, is
taken as a measure of vaccine immunogenicity in experi-
mental vaccine trials. Of the two types of assays, ICS has
the advantage of a highly multiparametric read-out (flow
cytometry) that allows for precise phenotyping of the
responding T cell populations. It has also recently been
adapted to a 96-well plate configuration [1,2], allowing
for higher throughput analysis similar to that used for
ELISPOT. However, while the precision of ELISPOT assays
across sites has been recently documented [3], similar
studies for ICS assays have been lacking.
Numerous phase I and phase II clinical trials have been
initiated using candidate prophylactic HIV vaccines
(reviewed in [4]). Many of these trials use ICS as part of
their immune monitoring. While most current HIV trials
are not powered to determine efficacy, and cytokine pro-
duction has not been validated as a surrogate marker of
protection from HIV infection or progression, there is nev-
ertheless a desire to measure immunogenicity of candi-
date vaccines as well as safety in early clinical trials [5].
Because many different groups are performing immune
monitoring for these clinical trials, there is currently a lack
of standardization that would allow accurate comparisons
of immunogenicity across candidate vaccines in different
clinical trials.
There is some published literature on the intra-and inter-
assay precision of ICS assays in whole blood [6]. These
values were determined to be about 8% and 20% C.V.,
respectively. Guidelines for performance of ICS assays
have also been recently published [7]. However, there are
no existing data documenting the precision of ICS
between laboratories, or comparing the precision of ICS
using different sample types (e.g., whole blood versus cry-
opreserved PBMC). In order to allow more meaningful
comparisons between laboratories and prioritization of
emerging vaccine candidates, and thereby accelerate HIV
vaccine development, this ICS standardization study was
undertaken.
The objectives of the study were three-fold: (1) to assess
the reproducibility of ICS assays using different sample
types (shipped whole blood vs. cryopreserved PBMC); (2)
to determine the inter-laboratory precision of ICS assays
among major HIV vaccine clinical research laboratories;
and (3) to improve the concordance of methodologies
used in these laboratories. To achieve these objectives,
joint experiments (Figure 1) were devised using (1) whole
blood activated at a central site, then fixed, frozen and
shipped to participating laboratories for processing andPage 2 of 18
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shipped to participating labs for activation, processing,
and analysis; and (3) cryopreserved PBMC shipped from
a central site to participating labs for activation, process-
ing, and analysis. In the latter case, this experiment was
also repeated with a larger number of participating labo-
ratories, using pre-formatted microtiter plates containing
lyophilised stimuli and lyophilised staining antibodies. In
each experiment, raw data files were also sent by the par-
ticipating labs to a central site for analysis, which was
done using a dynamic gating template and batch analysis
[1] (Figure 2).
Results
Activated, fixed, and frozen whole blood
In the first experiment, whole blood from three cytomeg-
alovirus (CMV)-seropositive donors was activated, fixed,
and frozen by the method described in Nomura et al.[6].
The blood was incubated for 6 hours in the presence of
brefeldin A, either with no stimulus, Staphylococcal enter-
otoxin B (SEB), or a mixture of overlapping peptides cor-
responding to the CMV pp65 protein [8-10]. Aliquots of
the frozen activated whole blood were then shipped to 9
laboratories for processing and analysis. The results, as
reported by each site and also as determined by central,
automated analysis of the raw data files, are summarized
in Figure 3. For data reported by each site, the mean inter-
lab C.V. was 55% for CD4 T cell responses and 32% for
CD8 T cell responses. This is higher than the inter-assay
C.V. previously reported for ICS assays performed at a sin-
gle site [6]. However, when the raw data was centrally ana-
lyzed, the inter-lab C.V. was reduced to 24% for both CD4
and CD8 T cell responses, very similar to the inter-assay
C.V. previously reported [6]. Thus, a large proportion of
the site-to-site variability could be explained by differ-
ences in gating of the ICS data.
Fresh whole blood
In a second experiment, whole blood from three CMV-
seropositive donors was shipped overnight to 6 U.S. labs
for activation, processing, and analysis. This experiment
was conducted twice, since the first trial was compromised
by shipping delays. The results of the second trial are
shown in Figure 4. As in Figure 3, the inter-lab C.V.'s were
higher for data reported by each site, although the reduc-
tion due to centralized analysis was less dramatic than in
Experimental designFigu e 1
Experimental design. (A) Schematic of protocol for Experiments 1–3, performed using liquid antigens and antibodies. (B) 
Schematic of protocol for Experiment 4, performed using lyophilised antigen and antibody plates.
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Manual versus automated gating templates. (A) Representative manual analysis of a CEF-stimulated sample from Exper-
iment 4. Sequential gates on small lymphocytes, CD3+ cells, and CD3+CD8+. cells are applied and the percent CD69+IFNg+ 
cells are determined from a plot gated on all of these regions. (B) Dynamic gating template for the same data file as above. 
Sequential dynamic gates ("Snap-To" gates) are applied as above, except that negative populations are also gated so as to pro-
vide a boundary for the movement of the positive region. The percent CD69+IFNg+ cells obtained is very similar to that 
obtained by manual gating in this example, since manual gating was performed so as to include CD3dim and CD8dim cells.
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BMC Immunology 2005, 6:13 http://www.biomedcentral.com/1471-2172/6/13Results of Experiment 1 (fixed activated whole blood)Fig re 3
Results of Experiment 1 (fixed activated whole blood). IFNγ-positive cells in response to SEB or CMV pp65 peptide 
mix are expressed as a percentage of CD4+ or CD8+ T cells. Results from each site are indicated as a circle, with median 
responses for each sample (105, 950, and 1040) indicated by a horizontal bar. The C.V. for each sample is listed across the top 
of each panel, along with the mean C.V. for that set of samples.
105 950 1040 105 950 1040
0.01
0.1
1
10
100
-----SEB----- -----CMV-----
105 950 1040 105 950 1040
0.01
0.1
1
10
100
-----SEB----- -----CMV-----
45% 36% 40% 91% 57% 60%
mean CV=55%
32% 28% 19% 14% 57% 41%
mean CV=32%
%
IF
N
γ+
c
e
lls
%
IF
N
γ+
c
e
lls
Individual (Manual) Analysis: Central (Automated) Analysis:
105 950 1040 105 950 1040
0.01
0.1
1
10
100
-----SEB----- -----CMV-----
105 950 1040 105 950 1040
0.01
0.1
1
10
100
-----SEB----- -----CMV-----
17% 16% 21% 37% 27% 24%
mean CV=24%
26% 20% 12% 14% 47% 23%
mean CV=24%
CD4 Responses
CD8 ResponsesPage 5 of 18
(page number not for citation purposes)
BMC Immunology 2005, 6:13 http://www.biomedcentral.com/1471-2172/6/13Results of Experiment 2 (shipped whole blood)Fig re 4
Results of Experiment 2 (shipped whole blood). IFNγ-positive cells in response to SEB or CMV pp65 peptide mix are 
expressed as a percentage of CD4+ or CD8+ T cells. Results from each site are indicated as a circle, with median responses for 
each sample (105, 1040, and 1090) indicated by a horizontal bar. The C.V. for each sample is listed across the top of each panel, 
along with the mean C.V. for that set of samples.
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provided to the labs between the first and second
experiment, so the smaller effect of centralized analysis
could be attributed to a progression of the individual sites
toward a more uniform gating scheme. Also, the relatively
high C.V. for CD4 T cell responses (42% even after cen-
tralized analysis) could be due to the low mean response
to CMV peptide mix in two of the donors (donors were
not identical in the different experiments). Since the C.V.
varies inversely with the mean of the sample population,
comparison of C.V.'s between experiments performed on
different donors are subject to this confounding variable.
Cryopreserved PBMC
In a third experiment, PBMC were isolated from 6 CMV-
seropositive donors and cryopreserved. Replicate cryopre-
served vials were sent to each of 7 sites, where they were
thawed, rested overnight, stimulated, processed, and ana-
lyzed. The post-thaw viability and recovery of the PBMC
samples from each site are shown in Figure 5. Mean via-
bilities were >82%, and mean recoveries were >75% for
each sample (determined by trypan blue exclusion). In
general, viabilities were quite consistent across labs, while
recoveries varied more widely, both between labs and
between samples. This could be due in part to imprecise
filling of the vials when they were initially frozen, which
would impact the apparent recoveries calculated upon
thawing. Furthermore, while a common thawing protocol
was provided, no attempt was made to standardize count-
ing methods or other factors that may impact the repro-
ducibility of viability and recovery calculations across
labs.
The ICS results from cryopreserved PBMC are shown in
Figure 6. The inter-lab C.V.'s for this experiment averaged
slightly lower than those for the whole blood experiments
(25–32% for manual analysis; 23–25% for centralized
automated analysis). Like the fresh whole blood experi-
ment, the improvement in C.V. from centralized analysis
was relatively small. When outlier samples with unusually
low responses were checked for viability and recovery,
they were not necessarily low in these parameters as well.
In fact, there was no obvious relationship of viability or
recovery with response, perhaps because viabilities and
recoveries were virtually all within generally acknowl-
edged limits of acceptability (>80% viability, >50% recov-
ery) [11,12].
Cryopreserved PBMC with preconfigured lyophilised 
reagent plates
To expand upon the results of the third experiment using
cryopreserved PBMC, a fourth experiment with this sam-
ple type was carried out using an enlarged cohort of par-
ticipating laboratories (table 1). In addition, a protocol
refinement was introduced to attempt to further reduce
inter-lab variability: Peptide stimuli together with brefel-
din A were provided in lyophilised form in appropriate
wells of a microtiter plate, to provide simplified assay set-
up; and lyophilised staining antibody cocktails were pro-
vided in the corresponding wells of a second microtiter
plate. These latter were rehydrated and added to the cells
in the first microtiter plate after fixation and permeabili-
zation of the cells. This experiment also sought to com-
pare two different types of staining antibody cocktails: the
two cocktails used in the previous three experiments (IFNγ
FITC/CD69 PE/CD4 PerCP-Cy5.5/CD3 APC and IFNγ
FITC/CD69 PE/CD8 PerCP-Cy5.5/CD3); and one that
combined CD4 and CD8 staining in a single sample, as
Viabilities and recoveries for cryopreserved PBMC samples used n Experiment 3F gure 5
Viabilities and recoveries for cryopreserved PBMC 
samples used in Experiment 3. Error bars represent SEM 
of the 6 sites participating.
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BMC Immunology 2005, 6:13 http://www.biomedcentral.com/1471-2172/6/13well as adding IL-2 staining (CD4 FITC/IFNγ +IL-2 PE/
CD8 PerCP-Cy5.5/CD3 APC).
The results of this experiment are shown in Figure 7 (note
the change to a linear scale in this and the following fig-
ures). A set of peptides consisting of epitopes from CMV,
Results of Experiment 3 (cryopreserved PBMC)Fig re 6
Results of Experiment 3 (cryopreserved PBMC). IFNγ-positive cells in response to SEB or CMV pp65 peptide mix are 
expressed as a percentage of CD4+ or CD8+ T cells. Results from each site are indicated as a circle, with median responses for 
each sample indicated by a horizontal bar. Sample names are listed along the X axis. The C.V. for each sample is listed across 
the top of each panel, along with the mean C.V. for that set of samples.
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trol, due to restrictions on international shipment of SEB.
CEF was expected to induce CD8, rather than CD4
responses, and indeed the CD4 responses to this control
were very low or negative. The CD8 responses, while pos-
itive, were considerably lower than those seen with SEB in
the previous experiments. Responses to CMV pp65 pep-
tide mix were also not high in the donors used in this
experiment, but were detectable in both CD4 and CD8
compartments. Despite the lower response means, the
average C.V. for this experiment was roughly similar to the
previous experiment, when comparing the same staining
antibody cocktails (cocktails 2 and 3). For unknown rea-
sons, the average C.V. for cocktail 1 (CD4/IFNγ +IL-2/
CD8/CD3) was higher than that for cocktails 2 and 3,
although the mean percentage of cytokine-positive cells
was not significantly different. The addition of IL-2 in this
cocktail did not significantly increase the mean percentage
of cytokine-positive cells, as very few cells responding to
CMV produce IL-2 without IFNγ [14]. This would not be
expected to be true for all types of responses, however.
When data for this experiment were centrally analysed
(Figure 7B), the average C.V.'s were considerably reduced,
much like in the first experiment (Figure 3). This could
reflect the fact that new laboratory sites had been added
that had not yet standardized their gating strategies with
the existing sites; thus more benefit was realized by cen-
tralized analysis. The difference in average C.V. between
cocktail 1 and cocktails 2 and 3 was preserved even after
centralized analysis. The mean C.V. for cocktails 2 and 3
was now 18%, the lowest variability seen in any of the
experiments. For comparison, the mean inter-lab C.V. of
the percent CD4+ or CD8+ cells in the unstimulated sam-
ples from this experiment was 3% and 7%, respectively
(data not shown).
Table 1: Study participants and institutions.
Institution (Consortium) Participants Participated in:
Exp. 1 
(fixed activated 
blood)
Exp. 2 
(shipped whole 
blood)
Exp. 3 
(cryo-preserved 
PBMC)
Exp. 4 
(cryo-preserved 
PBMC with 
lyoplates)
University of Montreal (CANVAC) Rafick Sekaly, Eva Roig, Claire 
Landry
x x x
Chelsea and Westminster Hospital 
(IAVI)
Jill Gilmour, Peter Hayes x x x
Uganda Virus Research Institute 
(IAVI)
Josephine Birungi, Omu Anzala x
Centre Hospitalier Universitaire 
Vaudois (EUROVAC)
Giuseppe Pantaleo, Alexandre 
Harari, Miguel Garcia
x x x
Fred Hutchison Cancer Research 
Center (HVTN)
Helen Horton ,Ruth Baydo, Ian 
Frank
x x x x
Duke University (HVTN) Kent Weinhold, Janet Ottinger, 
Megan Baker, Jennifer Holbrook
x x x
Vaccine Research Center, NIH Mario Roederer, Richard Koup, 
Laurie Lamoreaux
x x x x
Merck and Co. Timothy Tobery, Lynda Tussey, 
Kara Punt
x x x x
University of California, San 
Francisco
Barry Bredt, Elizabeth Sinclair, 
Lorrie Epling
x x x
BD Biosciences Vernon Maino, Holden Maecker, 
Maria Suni
x x x x
Sanofi Pasteur Nolwenn Nougarede, Sophia El-
Bahi
x
National Inst. Communicable 
Diseases, South Africa
Clive Gray, Hazel Maila x
Massachusetts General Hospital Marcus Altfeld, Gailet Alter x
University of Pennsylvania Jean Boyer, Sandra Calarota x
Henry Jackson Foundation Josephine Cox, Ellen Kuta x
Financial and Operational Support: Aline Rinfret, CANVAC; Patricia D'Souza, NIAID, NIH; Janice Darden, NIAID, NIHPage 9 of 18
(page number not for citation purposes)
BMC Immunology 2005, 6:13 http://www.biomedcentral.com/1471-2172/6/13Results of Experiment 4 (cryopreserved PBMC with lyophilized reagents)Fig re 7
Results of Experiment 4 (cryopreserved PBMC with lyophilized reagents). Cytokine-positive cells in response to 
CEF peptides or CMV pp65 peptide mix are expressed as a percentage of CD4+ or CD8+ T cells. Results from each site are 
indicated as a circle, with median responses for each sample indicated as a horizontal bar. Sample names are listed along the X 
axis. The C.V. for each positive sample is listed across the top of each panel, along with the mean C.V. for that set of samples. 
(A) Data reported by individual sites. (B) Data after centralized analysis using a dynamic gating template. Cocktail 1 consisted of 
CD4 FITC/IFNγ +IL-2 PE/CD8 PerCP-Cy5.5/CD3 APC. Cocktail 2 consisted of IFNγ FITC/CD69 PE/CD4 PerCP-Cy5.5/CD3 
APC, and cocktail 3 consisted of IFNγ FITC/CD69 PE/CD8 PerCP-Cy5.5/CD3 APC. (C) Control cell data from Experiment 4. 
Activated, processed, and stained PBMC were lyophilised and run as controls by each site in Experiment 4. These cells had 
been stained with cocktail 1, 2, or 3. The left panel shows data reported by individual sites; the right panel, data after central-
ized analysis using a dynamic gating template. Most of the inter-lab variability was removed by this method of analysis.
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As a positive control in Experiment 4, a set of PBMC were
SEB-activated, processed, stained, and then lyophilised in
certain wells of the lyophilised antibody plates. They were
hydrated and transferred to the plate containing activated
cells, along with the staining antibodies. These cells served
as a control for instrument setup and gating, since all the
activation and processing steps were done centrally. The
results reported by the individual sites for these cells are
shown in the left panel of Figure 7C. Surprisingly, the
average C.V. (20.5%) was only slightly lower than that for
the rest of Experiment 4, in which cells were activated and
processed independently by each site. However, when the
control cell data were centrally analysed using a dynamic
gating template (right panel), the C.V.'s were reduced to
3–7%. This reinforces the notion that the vast majority of
inter-lab variability is due to gating.
Spontaneous cytokine production in the three sample 
types
"Background" or spontaneous cytokine production (sub-
tracted from all data in Figures 3, 4, 6, and 7) is plotted for
all experiments in Figure 8. Backgrounds were generally
low. For all experiments combined, the mean CD4 back-
ground was 0.02% and the mean CD8 background was
0.05%. 98% of CD4 samples and 84% of CD8 samples
had backgrounds =0.1%. There were a significant number
of CD8 samples that exhibited high spontaneous cytokine
production. However, the mean CD8 background was sig-
nificantly higher than the mean CD4 background only in
the activated, fixed whole blood experiment (p < 0.0005).
When centralized automated analysis was applied to the
data, backgrounds were not usually reduced. This indi-
cates that the gains in reproducibility seen with central-
ized analysis were not simply due to reductions in
background.
While CD4 backgrounds were very similar between exper-
iments, CD8 backgrounds varied. The median CD8 back-
ground in the PBMC experiments was significantly lower
than that of the frozen activated whole blood experiment
(p < 0.0001) or the fresh whole blood experiment (p <
0.05). The differences were significant after centralized
analysis as well. However, this could be due to the fact
that different donors were used in the four experiments,
rather than being due to any inherent difference between
assay types. In experiment 4, the CD4 backgrounds for
cocktail 1 were significantly higher than those for cocktail
2 (p < 0.05, data not shown), while there was no signifi-
cant difference for CD8 backgrounds. This could be due to
the inclusion of IL-2 in cocktail 1, which would be
expected to be produced by more CD4+ than CD8+ cells,
and thus contribute selectively to the CD4 background.
Discussion
This study examined the reproducibility of ICS assays
across sites using different assay formats. It was not
designed to compare ICS with other immune monitoring
assays, comparisons of which have been published [15-
21]. The current study used 96-well plate-based protocols
exclusively, as these were considered more convenient,
Background cytokine-producing cells by experimentFigure 8
Background cytokine-producing cells by experiment. 
Cytokine-positive cells in the absence of stimulus are 
expressed as a percentage of CD4+ or CD8+ T cells. Each 
symbol represents the background from a single sample 
processed by a single site. Medians are shown by a horizontal 
bar. Data from experiment 4 are for cocktails 2 and 3 only, 
to be comparable with experiments 1–3.
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BMC Immunology 2005, 6:13 http://www.biomedcentral.com/1471-2172/6/13and have recently been validated against tube-based pro-
tocols for both PBMC and whole blood [1].
Lyophilised reagents in plates were used for Experiment 4.
These have been extensively compared to liquid reagents
([22] and Figure 9) and shown to be largely equivalent. In
addition to convenience of assay set-up, the lyophilised
reagent plates offer long reagent stability, even at room
temperature (>1 year, data not shown), and a potential
reduction in errors caused by incorrect reagent addition.
Intra-plate variability using lyophilised reagents was
determined to be <10% in ICS assays (data not shown).
There are some potential drawbacks to the use of 96-well
plates. One of these is the possibility of well-to-well con-
tamination during the assay. This was observed in an ini-
tial subset of Experiment 4 (data not shown), in which
some sites received lyophilised plates with SEB as a posi-
tive control. Some of these sites experienced high back-
grounds in the negative control wells adjacent to the SEB-
containing wells. It was later determined that cross-con-
tamination probably occurred during the initial distribu-
tion of the antigens on the plates, and this was
compounded by the fact that the donors used were unu-
sually sensitive to SEB stimulation (responses >30% of
CD4+ and CD8+ T cells). When SEB was replaced with CEF
as a positive control, no such problems were noted. This
experience suggests that the choice and placement of pos-
itive control wells on a plate deserves consideration.
The current study was designed to determine inter-lab var-
iability in ICS assays. As such, there were no data "filters"
applied to exclude potentially erroneous data or outliers.
However, improved precision of ICS results might be
obtained if certain acceptance criteria were applied before
data were taken as valid. For example, a minimum
number of collected events could be specified (sites in this
study were asked to collect 10,000–40,000 CD4+ or CD8+
T cells per sample, or 60,000 CD3+ cells). This number of
events was designed to yield precision levels that would
minimize event number as a factor in inter-lab reproduc-
ibility. There could also be acceptance criteria based upon
the absolute level of background, or the degree of repro-
ducibility between duplicate samples, if run (the current
study did not use duplicate samples).
It is also possible to apply statistics to derive further mean-
ing from numerical results. For example, statistical tests
could be used to determine whether a given response can
be discriminated from a given background, for a particular
number of events collected [23,24]. This can be given by a
power calculation as follows:
N = [2*Pav(1-Pav)(Zα +Zβ)2]/∆2
where N is the number of events in each sample needed
for significance, Pav is the average proportion (between the
background and test samples), and ∆ is the difference
between these two proportions. The term (Zα +Zβ)2 is
referred to as a power index, and varies depending upon
the desired power and p value. For example, (Zα +Zβ)2 =
23.9 for 99% power and p < 0.005 [23].
In addition, a confidence interval could be derived
around the difference of the test result and the negative
control [24], in order to allow discrimination of signifi-
cant differences between various samples. Other statistical
methods have also been employed in order to determine
cut-off values for positive responses in ICS [25,26]. No
attempt was made in the current study to define which
results were positive, as all data were reported objectively,
and all donors were known to be CMV seropositive.
Examination of the data from Figures 3, 4, 6, and 7 sug-
gests that samples with a low number of cytokine-positive
cells had higher variability than samples with a high
number of cytokine-positive cells. The relationship of
response level and C.V. is summarized in Table 2 for all
assays (CD4 and CD8, whole blood and PBMC) consid-
ered together. These data emphasize the difficulty of
achieving precise results at response levels of less than
0.1% of CD4 or CD8 T cells. For these samples, collecting
even more events than what was suggested would be
expected to improve precision, per the discussion above.
The average C.V. across the four experiments is summa-
rized in Table 3. These data are confounded by the fact
that different donors and different laboratories partici-
pated in the four experiments. However, variability due to
individual analysis can be excluded by comparing only
centrally analysed data (bottom row of Table 3). Assum-
ing no effect from the other confounding variables, we
found that Experiment 4 (cryopreserved PBMC with lyo-
plates) yielded a significantly lower average C.V. than
Experiment 2 (shipped whole blood) (p < 0.05). Also, the
average C.V. of centrally analysed data from all experi-
ments was significantly lower than that of individually
analysed data (p < 0.0001). This highlights the amount of
variability in each experiment that is due to gating differ-
ences between sites.
Mitigation of gating variability was achieved in these
experiments by centralized analysis with a dynamic gating
template (see Figure 2B). The dynamic gating template
allowed for more automated, batch analysis of the data.
Once such a template was created and optimized (see
Materials and Methods section for description), it could
also have been provided to individual sites in order to
yield the same results. It is further possible that similar
results could be achieved by manual analysis, provided itPage 12 of 18
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BMC Immunology 2005, 6:13 http://www.biomedcentral.com/1471-2172/6/13Comparison of liquid and lyophilised reagentsFigure 9
Comparison of liquid and lyophilised reagents. Comparative results are shown with backgrounds subtracted; no signifi-
cant differences in backgrounds were seen with liquid versus lyophilised reagents (data not shown). (A) Data from one site that 
compared cocktail 1 (CD4 FITC/IFNγ +IL-2 PE/CD8 PerCP-Cy5.5/CD3 APC) in liquid and lyophilised form in Experiment 4. 
Black bars indicate liquid antibodies, grey bars indicate lyophilised antibodies. Error bars indicate SEM of duplicate wells. (B) 
Combined comparison of liquid antigen + liquid antibodies versus lyophilised antigen + lyophilised antibodies. Whole blood was 
activated with either SEB or pp65 peptide mix, and the percentage of IFNγ+ cells (CD4+ or CD8+) were compared with liquid 
versus lyophilised reagents (left panel). A similar comparison was made for the mean fluorescence intensity (MFI) of IFNγ+ cells 
(CD4+ or CD8+) (right panel). Similar results were obtained using PBMC (not shown).
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BMC Immunology 2005, 6:13 http://www.biomedcentral.com/1471-2172/6/13was done by a single operator. Standardization of gating
techniques, in the absence of centralized analysis or
dynamic gating templates, could also improve precision.
The improvement in C.V. made by centralized analysis
was most marked in the first experiment, and progres-
sively less in experiments 2 and 3, perhaps because of
standardization of gating among sites over time.
Experiment 4 included many new sites, and the improve-
ment in C.V. from centralized analysis was again more
marked.
Because the C.V. varies as a function of the response level
(Table 2), it is possible that differences in mean C.V.
between assay formats were due to the number of low ver-
sus high responders in each experiment (since different
donors were used in the four experiments). Also, the C.V.
is highly sensitive to small changes in the mean, when the
mean is a very low number. Therefore, an analysis of S.D.
versus mean was also performed for the four experiments
(Figure 10). This data confirms the data of Table 3, indi-
cating that the three assay formats showed grossly similar
reproducibility. However, when analysis variability was
removed, cryopreserved PBMC assays appeared to be
slightly more reproducible than shipped whole blood
assays. This seemed especially apparent in experiment 4,
where lyophilised reagents were used.
In addition to differences in reproducibility, the various
assay formats have other benefits and drawbacks as well.
Cryopreserved PBMC are much more amenable to peptide
(and superantigen) stimulation than to whole protein
stimulation [9]; while whole blood assays are equally
amenable to stimulation with either type of antigen. Also,
consistently good cryopreservation of PBMC at multiple
clinical sites is difficult to achieve, but highly important
for achieving reproducible results with PBMC [27,28]
(DeLaRosa et al., manuscript in preparation). This could
become less of a factor if a stabilizing matrix for preserv-
ing whole blood or PBMC function during shipping were
discovered. All in all, the choice of assay format for a clin-
ical trial will depend not only upon considerations of
assay precision, but also upon the type of antigen(s) used
and the capabilities of the participating clinical sites.
The use of lyophilised reagent plates appeared to reduce
inter-lab variability. This conclusion cannot be drawn
with certainty, because different participating laboratories
and different donors were used between experiments 3
and 4. However, it is intriguing to note that, when cen-
trally analysed data was compared (to remove gating as a
source of variability), the mean C.V.'s of experiment 4
were the lowest of all four experiments (18%, Table 3).
This is despite the fact that the donors and stimuli used in
experiment 4 resulted in lower mean response levels,
which should tend to increase the C.V. This is also borne
out by the analysis of Figure 11B, where the results for
experiment 4 appeared to be generally closer to the
theoretical minimum SD than did the results for the other
experiments.
With the possibility of achieving inter-laboratory C.V.'s of
less than 20%, even with relatively low responses, ICS
compares favourably to ELISPOT, for which interassay
C.V.'s of 17–18% for PHA and 55–65% for Candida have
Table 2: Percent C.V. by mean percent cytokine-positive T cells.
Mean % cytokine-positive cells = 0.1% 0.1 – 0.5% >0.5%
Number of samples in range 6 6 35
Average percent C.V. Individual (Manual) Analysis 71% 31% 21%
Central (Automated) Analysis 56% 25% 18%
Table 3: Percent C.V. by assay format.
Assay Type Fixed Activated 
Blood
Shipped Whole 
Blood
Cryopreserved 
PBMC
Cryopreserved PBMC 
with lyophilised 
reagents
Number of samples 12 12 24 9
Average percent C.V. Individual (Manual) Analysis 44% 38% 28% 39%
Central (Automated) Analysis 24% 31% 23% 18%Page 14 of 18
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S.D. versus mean for all assays. A linear relationship between S.D. and mean is expected based upon counting statistics 
[23]. This expected relationship (for a data set of 40,000 events) is shown by the solid black line. The actual data from the four 
experiments is shown in the symbols. Data from experiment 4 are for cocktails 2 and 3 only, to be comparable with experi-
ments 1–3. The difference (in the Y dimension) between the data points and the solid line represents variability from sources 
other than counting statistics. Note that the data points for all three assay types cluster together, indicating that variability is 
similar for all three assay types. When individual analysis variability is removed (B), there is a slight tendency toward lower var-
iability with cryopreserved PBMC (solid circles), and higher variability with shipped whole blood (open squares). The tendency 
toward lower variability is more pronounced in the experiment using cryopreserved PBMC with lyophilised reagents (panel B, 
open circles).
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ELISA, the latter having reported interassay C.V.'s of <25%
[31,32]. Phenotypic staining, such as used for CD4 count-
ing, can achieve higher precision levels than functional
assays, and averaged around 10% C.V. in one multisite
study [33]. For comparison, the inter-lab C.V. of the CD4+
or CD8+ cell percentages was around 5% in experiment 4
of the present study (data not shown). CD4 counting pre-
cision has also been shown to be dependent upon the
number of events collected, gating, and use of automated
analysis [33,34]. Since functional assays are subject to
more variables than phenotypic staining, the ability to
achieve precision levels such as those reported here
should be considered favourable. ICS could thus be a via-
ble tool for comparing immune responses even across
clinical trials, provided the methodology was
standardized.
Conclusion
ICS assays could be performed with inter-laboratory C.V.'s
of approximately 20% at response levels of >0.5%, and
C.V.'s of approximately 25–30% at response levels of 0.1–
0.5%. The C.V. increased further at response levels of
=0.1%. A significant portion of inter-laboratory variability
could be eliminated by use of centralized analysis and/or
a dynamic gating template.
Whole blood and cryopreserved PBMC showed grossly
similar levels of reproducibility. However, when analysis
variability was removed, cryopreserved PBMC processed
with lyophilized reagents showed significantly better
reproducibility than shipped whole blood. Shipped
whole blood assays were also subject to data loss when
samples were not delivered in a timely fashion.
Background cytokine production was mostly =0.05% for
both CD4 and CD8 cells. While CD8 backgrounds were
lower in cryopreserved PBMC than in whole blood, this
could have been due to the use of different donors in the
four experiments. With the high viabilities and recoveries
obtained for cryopreserved PBMC in this study, there was
no obvious relationship between viability/recovery and
response.
The use of microtiter plates containing lyophilised rea-
gents simplified the ICS protocol, and appeared to
improve assay reproducibility. This format lends itself to
international shipping of reagents (because there is no
need for refrigeration), and also to larger clinical trials
(because of the stability of the lyophilised reagents). It is
also a way to reduce the chance of pipetting errors,
because the plates are pre-formatted.
The results of this study indicate that ICS assays can be rea-
sonably standardized between sites, but that considera-
tions of sample format and expected response levels can
influence the precision of the results. These data should
guide comparisons of ICS results between different groups
or in different clinical trials.
Methods
Whole blood preparation
Heparinized whole blood was collected from healthy
CMV seropositive volunteers for experiments 1 and 2. For
experiment 1, the blood was activated in 15 mL conical
tubes according to the method of Nomura et al.[6]. Acti-
vated blood was treated with 2 mM final concentration of
EDTA for 15 minutes at room temperature, then 10
volumes of FACS Lysing Solution (BD Biosciences, San
Jose, CA) were added. After 10 minutes at room tempera-
ture, the tubes were frozen at -80°C, then shipped to par-
ticipating laboratories on dry ice. The protocol used by
each laboratory for handling these samples is provided in
Additional File 1.
For experiment 2, 5 mL of heparinized whole blood was
overnight shipped in an insulated container at ambient
temperature to each participating lab. The protocol used
by each lab for handling these samples is provided in
Additional File 2.
PBMC preparation and cryopreservation
For experiments 3 and 4, PBMC from leukapheresis of
CMV seropositive donors were isolated using Ficoll gradi-
ent separation. They were then cryopreserved according to
a standard protocol (Disis et al., submitted for
publication). These cryopreserved PBMC were shipped to
participating labs using liquid nitrogen dry shippers. The
protocol used by each lab for thawing and processing of
these cells is provided as Additional Files 3 and 4.
Instrumentation and setup
The flow cytometry instrumentation used in this study
included 12 BD FACS Caliburs (BD Biosciences), 3 BD
LSRIIs (BD Biosciences), and 1 CyAn (Dako Cytomation,
Fort Collins, CO). Instrument setup was at the discretion
of the individual laboratory, and was either manual
(using isotype control stained cells to set PMT voltages,
and single-stained cells to set compensation) or
automated (using BD FACSComp software and BD Cal-
ibrite beads (BD Biosciences)). In some labs, automated
setup was followed by manual adjustment using stained
cells as above.
Dynamic gating templates
Original FCS files from each site were sent to BD Bio-
sciences for analysis using a dynamic gating template (Fig-
ure 2B). This template was built using "Snap-To Gating"
and "Tethering" tools available in CellQuest Pro software
(BD Biosciences). The shape of the snap-to gates is deter-Page 16 of 18
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allows for their movement from sample to sample in a
data-dependent manner. The size and amount of allowa-
ble movement of each snap-to gate was adjusted by
inspection of a subset of the files to be used, with iterative
changes being made until the template performed as
desired. The template was then used, without further
adjustment, on all the files of a given experiment. Since
the template was generated in CellQuest Pro software,
only files generated on FACS Calibur instruments were
analyzable by this method.
Statistical analyses
The %CV was calculated as 100*SD/mean for each sam-
ple, from the percentage of cytokine-positive cells
reported by each laboratory or derived from centralized
analysis of that sample. The mean CV for each experiment
was taken as the average of all the individual sample CVs.
Statistical significance of differences in the average CV
between experiments was calculated using a Kruskal-Wal-
lis test, with Dunn's Multiple Comparison test to deter-
mine where significant differences were found. The
significance of the difference between individually and
centrally analyzed data was calculated by comparing the
aggregate CVs of all samples from all experiments using a
Wilcoxin signed rank test for matched pairs. A two-tailed
Student t test was used to calculate significance of differ-
ences in background within or between experiments.
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